Brian Levy

Company: InflammX Therapeutics

Job title: Chief Executive Officer

Seminars:

Novel Orally Administered Small Molecule (Xiflam) Targeting Auto- Inflammation in Patients with Intermediate AMD 9:30 am

Understanding the pathological Cx43 hemichannel and its role in inflammasome mediated disease progression in intermediate AMD Clinically developing a novel oral therapy to inhibit the pathologically open Cx43 hemichannel to modulate ATP activation and perpetuation of the inflammasome. Sharing preclinical data showing the effect of Xiflam vs Placebo in maintaining retinal integrity and visual function,…Read more

day: Conference Day Two